NAGASAKI UNIVERSITY GLOBAL COE PROGRAM - Global Strategic Center for Radiation Health Risk Control
Nagasaki University
Home>Activities>Reports on Overseas' Conferences and Meetings>Bulletin report on the Peripheral T-cell Lymphoma Forum
Reports on Overseas' Conferences and Meetings
Bulletin report on the Peripheral T-cell Lymphoma Forum

Kunihiro Tsukasaki, Department of Molecular Medicine and Hematology

The Peripheral T-cell Lymphoma Forum was held in September 18-20, 2008, at Washington, DC. This forum provided a platform for discussion about the diagnosis, classification, current treatment options, and novel approaches for PTCL that include more than ten disease entities. I attended the meeting because the incidence of peripheral T-cell lymphomas (PTCL), a type of non-Hodgkin’s lymphoma (NHL), is high in Japan especially south-west coast of Kyusyu.

In the session of state of arts on the treatment for PTCL, Dr. Tobinai at National Cancer Center, Japan, presented our data on adult T-cell leukemia-lymphoma (ATL). A phase 3 study of 118 ATL patients compared biweekly CHOP with multiagent chemotherapy of VCAP-AMP-VECP, supported by G-CSF. The complete response rate was 40% in the VCAP-AMP-VECP arm and 25% in the CHOP arm. He concluded that the median survival time of 13 months with VCAPAMP-VECP as compared to 11 months with biweekly CHOP is still not satisfactory, , but this should be the basis for future study in the treatmentof ATL.

In contrast to rituximab, anti-CD20 monoclonal antibody, for the treatment of B-cell lymphoma, no molecular targeting agent is available for PTCL. In the meeting, several kinds of promising agents for the diseases were presented, including monoclonal antibodies targeting CD2, CD4, CD25, CD52 and CCR4, histone deacetylase inhibitor, proteasome inhibitor, novel nucleoside analogs, novel folate analogs and signal transduction inhibitors. We presented the preliminary results of a phase 1 trial of nobel agent, ant-CCR4 antibody ongoing in Japan. CCR4 is a chemokine receptor expressed in most ATL and about one third of unspecified PTCL, The results showed relative safety and some efficacy of the antibody.

Among other topics, allogeneic stem cell transplantation for young patient and praratrexate, a novel folate analog, were apparently promising.

The next Peripheral T-cell Lymphoma Forum will be held in Bologna, Italy, in next year. .
  International Radiation Health Sciences Research
    Atomic Bomb Disease Medicine Research
    Radiation Basic Life Sciences Research
    Workshop / Special Meeting
    Academic Exchange
    Reports on Overseas' Conferences and Meetings
    Cooperation with WHO
Publicity Activities
  Truth of radiology (in Japanese)
  Radiation Q&A (in Japanese)
    Introduction of Global Strategic Center for Radiation Health Risk Control
(in Japanese) [PDF 9MB]
    Visiting Report of Chelnobyl
Yasuyuki Taira, Graduate Student
Related Links